Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19357447 | ANAPLASTIC LYMPHOMA KINASE (ALK) DEGRADERS AND USES THEREOF | October 2025 | January 2026 | Allow | 3 | 0 | 0 | No | No |
| 19311344 | Selective Serotonin Receptor Modulators and Methods of Making and Using the Same | August 2025 | January 2026 | Allow | 5 | 1 | 1 | Yes | No |
| 19096210 | METHODS FOR TREATING NEUTROPENIA | March 2025 | June 2025 | Allow | 3 | 0 | 0 | No | No |
| 19029360 | METHODS AND COMPOSITIONS FOR TREATMENT OF MYDRIASIS | January 2025 | October 2025 | Allow | 9 | 1 | 1 | No | No |
| 19029592 | METHODS AND COMPOSITIONS FOR TREATMENT OF MYDRIASIS | January 2025 | November 2025 | Allow | 10 | 1 | 1 | No | No |
| 19001859 | AGENT FOR INHIBITING RENAL DAMAGE INDUCED BY RHABDOMYOLYSIS | December 2024 | October 2025 | Abandon | 10 | 1 | 0 | Yes | No |
| 18271036 | HYDROXYPENTYL BENZOIC ACID DIESTER COMPOUND, AND PREPARATION METHOD AND PHARMACEUTICAL APPLICATION THEREOF | September 2024 | June 2025 | Allow | 24 | 0 | 1 | No | No |
| 18794778 | STABLE LIQUID COMPOSITIONS OF NETUPITANT AND PALONOSETRON | August 2024 | March 2025 | Allow | 8 | 1 | 1 | Yes | No |
| 18629099 | METHODS OF TREATING ACUTE CORONARY SYNDROME USING 3,3'-DIINDOLYLMETHANE | April 2024 | September 2025 | Allow | 18 | 1 | 1 | Yes | No |
| 18621624 | PRESBYOPIA TREATMENTS | March 2024 | October 2025 | Abandon | 19 | 1 | 1 | No | No |
| 18612665 | CHEMICALLY MODIFIED CURCUMINS FOR USE IN THE PRODUCTION OF LIPOXINS | March 2024 | March 2026 | Abandon | 23 | 2 | 1 | No | No |
| 18588730 | CAPSID INHIBITORS FOR THE TREATMENT OF HIV | February 2024 | February 2026 | Allow | 24 | 2 | 0 | Yes | Yes |
| 18583643 | TETRACYCLINE COMPOSITIONS | February 2024 | August 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18444310 | READY-TO-USE INJECTABLE PHARMACEUTICAL COMPOSITIONS COMPRISING NEOSTIGMINE AND GLYCOPYRROLATE | February 2024 | August 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18442061 | COMPOSITIONS AND METHODS FOR TREATING EPILEPSY | February 2024 | November 2024 | Allow | 9 | 1 | 1 | No | No |
| 18440388 | ARIPIPRAZOLE FORMULATIONS HAVING INCREASED INJECTION SPEEDS | February 2024 | February 2026 | Allow | 24 | 2 | 1 | Yes | No |
| 18417252 | COMPOSITIONS AND METHODS FOR TREATING EPILEPSY | January 2024 | December 2024 | Allow | 11 | 2 | 1 | No | No |
| 18413666 | ACID ADDITION SALTS OF BENZIMIDAZOLE DERIVATIVE | January 2024 | March 2025 | Allow | 14 | 1 | 1 | No | No |
| 18405907 | COMBINATION COMPOSITION | January 2024 | September 2024 | Allow | 9 | 1 | 0 | No | No |
| 18391876 | ANTAGONIST OF THE FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) FOR USE IN THE TREATMENT OR THE PREVENTION OF SKELETAL DISORDERS LINKED WITH ABNORMAL ACTIVATION OF FGFR3 | December 2023 | March 2025 | Abandon | 15 | 1 | 0 | No | No |
| 18393055 | TREATMENT OF AVASCULAR OR HYPOVASCULAR MICRO-TUMORS | December 2023 | March 2025 | Abandon | 15 | 1 | 0 | No | No |
| 18545754 | USE OF CANNABIDIOL IN THE TREATMENT OF NOCTURNAL SNORING | December 2023 | February 2025 | Abandon | 14 | 1 | 0 | No | No |
| 18532133 | METAL SALTS AND USES THEREOF | December 2023 | November 2024 | Allow | 11 | 1 | 0 | No | No |
| 18529497 | NOVEL WATER SOLUBLE NANO-SIZED IMINE RU(III) COMPLEX BASED ON 4-AMINOBENZENE SODIUM SULPHONATE FOR BIOMEDICAL APPLICATIONS | December 2023 | March 2024 | Allow | 3 | 0 | 2 | Yes | No |
| 18516174 | PROCASPASE COMBINATION THERAPY FOR GLIOBLASTOMA | November 2023 | June 2025 | Allow | 18 | 2 | 0 | Yes | No |
| 18381524 | METHODS FOR TREATMENT OF DISEASES | October 2023 | September 2025 | Abandon | 23 | 0 | 1 | No | No |
| 18487329 | FREEZE DRIED DRUG NANOSUSPENSIONS | October 2023 | June 2025 | Abandon | 20 | 0 | 1 | No | No |
| 18485799 | COMBINATIONS OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2 ADRENORECEPTOR AGONIST | October 2023 | December 2024 | Allow | 15 | 1 | 0 | No | No |
| 18376308 | DISINFECTING COMPOSITION, APPLICATOR, AND METHOD OF DISINFECTING | October 2023 | August 2025 | Abandon | 22 | 2 | 1 | No | No |
| 18450394 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | August 2023 | June 2025 | Abandon | 22 | 1 | 1 | No | No |
| 18232551 | PHYTOESTROGEN PRODUCT OF RED CLOVER AND PHARMACEUTICAL USES THEREOF | August 2023 | November 2024 | Abandon | 15 | 1 | 0 | No | No |
| 18364880 | USE OF A COMBINATION OF SACUBITRIL AND VALSARTAN | August 2023 | December 2024 | Abandon | 16 | 1 | 0 | No | No |
| 18360752 | HDAC6 INHIBITORS FOR TREATMENT OF METABOLIC DISEASE AND HFPEF | July 2023 | October 2024 | Allow | 15 | 3 | 1 | No | No |
| 18225252 | COMPOSITIONS AND METHODS FOR TREATING EPILEPSY | July 2023 | January 2024 | Allow | 6 | 0 | 2 | Yes | No |
| 18351682 | METHODS OF USING A PHENOXYPROPYLAMINE COMPOUND TO TREAT PAIN | July 2023 | October 2025 | Abandon | 28 | 2 | 0 | No | Yes |
| 18217045 | METHODS OF REDUCING THE RISK OF A CARDIOVASCULAR EVENT IN A SUBJECT ON STATIN THERAPY | June 2023 | September 2024 | Abandon | 14 | 1 | 0 | Yes | No |
| 18334690 | EPINEPHRINE SPRAY FORMULATIONS | June 2023 | July 2024 | Allow | 13 | 2 | 0 | Yes | No |
| 18323435 | ANTIPLATELET DRUGS AND USES THEREOF | May 2023 | August 2023 | Allow | 3 | 0 | 0 | No | No |
| 18037102 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND ANTIBIOTIC COMPOSITION COMPRISING SAME | May 2023 | February 2026 | Allow | 33 | 1 | 1 | No | No |
| 18316911 | INJECTABLE SUSTAINED RELEASE BUPRENORPHINE FORMULATION | May 2023 | May 2024 | Allow | 12 | 4 | 0 | Yes | No |
| 18139349 | USE OF FENOLDOPAM FOR THE TREATMENT OF HEMOLYTIC UREMIC SYNDROME | April 2023 | March 2025 | Abandon | 23 | 2 | 0 | No | No |
| 18305303 | DOSAGE REGIMEN OF PALIPERIDONE PALMITATE EXTENDED-RELEASE INJECTABLE SUSPENSION | April 2023 | September 2024 | Allow | 17 | 1 | 0 | No | No |
| 18247415 | AGENT FOR INHIBITING RENAL DAMAGE INDUCED BY RHABDOMYOLYSIS | March 2023 | May 2025 | Abandon | 25 | 1 | 0 | No | No |
| 18187507 | OPHTHALMIC GEL COMPOSITIONS OF BIMATOPROST AND TIMOLOL AND ASSOCIATED METHODS | March 2023 | May 2024 | Allow | 14 | 3 | 0 | No | No |
| 18187471 | ENHANCED PENETRATION OPHTHALMIC COMPOSITIONS OF BIMATOPROST AND TIMOLOL | March 2023 | February 2024 | Allow | 11 | 2 | 0 | Yes | No |
| 18115286 | USES OF OXYGENATED CHOLESTEROL SULFATES (OCS) | February 2023 | March 2026 | Abandon | 37 | 1 | 0 | No | No |
| 18110879 | LIPOPHILIC ACTIVE ORAL FILM FORMULATION AND METHOD OF MAKING THE SAME | February 2023 | December 2025 | Allow | 34 | 2 | 1 | Yes | No |
| 18104970 | TREATMENT OF POST-OPERATIVE PAIN VIA SCIATIC NERVE BLOCK WITH SUSTAINED-RELEASE LIPOSOMAL ANESTHETIC COMPOSITIONS | February 2023 | January 2024 | Allow | 11 | 2 | 0 | No | No |
| 18018576 | ANTIPLATELET DRUGS AND USES THEREOF | January 2023 | April 2025 | Allow | 26 | 1 | 1 | No | No |
| 18154550 | USE OF N-ACETYLCYSTEINE TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS | January 2023 | February 2024 | Allow | 13 | 2 | 0 | Yes | No |
| 18086141 | DICARBOXYLIC ACID BISAMIDE DERIVATIVES, USE THEREOF, PHARMACEUTICAL COMPOSITION BASED THEREON AND METHODS FOR PRODUCING DICARBOXYLIC ACID BISAMIDE DERIVATIVES | December 2022 | September 2025 | Abandon | 33 | 2 | 1 | Yes | No |
| 18069204 | STABLE LIQUID COMPOSITIONS OF NETUPITANT AND PALONOSETRON | December 2022 | July 2024 | Allow | 19 | 2 | 1 | No | No |
| 18065400 | COMBINATIONS OF BETA-LACTAM COMPOUNDS AND PROBENECID AND USES THEREOF | December 2022 | July 2024 | Allow | 19 | 1 | 0 | No | No |
| 18064587 | ABIRATERONE ACETATE CONTAINING COMPOSITION AND APPLICATION THEREOF | December 2022 | July 2023 | Allow | 7 | 0 | 1 | No | No |
| 18061562 | PHARMACEUTICAL COMPOSITION FOR THE PARENTERAL ADMINISTRATION OF ULTRASHORT-EFFECTIVE BETA-ADRENORECEPTOR ANTAGONISTS | December 2022 | April 2024 | Abandon | 16 | 1 | 0 | No | No |
| 18059177 | TREATMENT OF IMMUNE-RELATED AND INFLAMMATORY DISEASES | November 2022 | April 2024 | Abandon | 17 | 1 | 0 | No | No |
| 17927053 | N-(1-CYANO-PYRROLIDIN-3-YL)-5-(3-(TRIFLUOROMETHYL)PHENYL)OXAZOLE-2-CARBOXAMIDE DERIVATIVES AND THE CORRESPONDING OXADIAZOLE DERIVATIVES AS USP30 INHIBITORS FOR THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION | November 2022 | January 2026 | Abandon | 38 | 0 | 1 | No | No |
| 17990806 | ACID ADDITION SALTS OF BENZIMIDAZOLE DERIVATIVE | November 2022 | October 2023 | Allow | 10 | 0 | 0 | No | No |
| 18057116 | LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HFpEF) | November 2022 | May 2023 | Allow | 6 | 1 | 0 | Yes | No |
| 18054111 | METHODS FOR IMPROVED ENDOVASCULAR THROMBECTOMY USING 3,3'-DIINDOLYLMETHANE | November 2022 | January 2024 | Allow | 14 | 2 | 1 | No | No |
| 17997393 | LERIGLITAZONE FOR TREATING LUNG INFLAMMATION AND INTERSTITIAL LUNG DISEASE | October 2022 | December 2025 | Abandon | 38 | 0 | 1 | No | No |
| 17922083 | APPLICATION OF HETEROCYCLIC COMPOUND | October 2022 | December 2025 | Abandon | 38 | 0 | 1 | No | No |
| 17935839 | COMBINED TREATMENT REGIMEN OF ANESTHESIA/SEDATION WITH ADMINISTRATION OF PSYCHEDELIC DRUGS ASSOCIATED WITH REDUCTION IN NEUROPSYCHIATRIC ILLNESS | September 2022 | December 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17948842 | SUSTAINED RELEASE DEXAMETHASONE FORMULATION | September 2022 | October 2025 | Abandon | 37 | 3 | 0 | No | No |
| 17943708 | COMBINATION COMPOSITION | September 2022 | October 2023 | Allow | 13 | 0 | 0 | No | No |
| 17941509 | METHODS FOR TREATING NEUTROPENIA | September 2022 | March 2025 | Allow | 30 | 4 | 1 | Yes | No |
| 17821699 | METAL SALTS AND USES THEREOF | August 2022 | September 2023 | Allow | 12 | 0 | 0 | Yes | No |
| 17889029 | PANOBINOSTAT DOSAGES FOR MULTIPLE MYELOMA | August 2022 | February 2024 | Abandon | 18 | 1 | 0 | No | No |
| 17881874 | DOSING REGIMENS FOR 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE | August 2022 | August 2023 | Allow | 12 | 0 | 0 | Yes | No |
| 17882458 | FORMULATIONS WITH ENHANCED SN-38 SOLUBILITY AND ORAL ABSORPTION | August 2022 | April 2025 | Allow | 32 | 3 | 1 | Yes | No |
| 17877558 | METHODS AND COMPOSITIONS FOR TREATMENT OF MYDRIASIS | July 2022 | September 2024 | Allow | 25 | 3 | 0 | Yes | No |
| 17877564 | METHODS AND COMPOSITIONS FOR TREATMENT OF MYDRIASIS | July 2022 | September 2024 | Allow | 25 | 3 | 0 | Yes | No |
| 17870855 | INHIBITING DIHYDROFOLATE REDUCTASE IN A MICROORGANISM | July 2022 | November 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17863250 | CARBONIC ACID ADDUCTS | July 2022 | July 2025 | Allow | 36 | 3 | 0 | No | No |
| 17811021 | MODULATORS OF TDP-43 | July 2022 | January 2024 | Abandon | 18 | 2 | 1 | No | No |
| 17809733 | COMPOUNDS FOR REDUCING THE VISCOSITY OF BIOLOGICAL FORMULATIONS | June 2022 | August 2025 | Allow | 37 | 2 | 1 | No | No |
| 17809745 | ARIPIPRAZOLE FORMULATIONS HAVING INCREASED INJECTION SPEEDS | June 2022 | November 2023 | Allow | 16 | 1 | 0 | No | No |
| 17806575 | ANTI-INFLAMMATORY COMPOUNDS AND USES THEREOF | June 2022 | March 2024 | Abandon | 21 | 1 | 0 | No | No |
| 17784593 | THERAPEUTIC COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF DIASTOLIC DYSFUNCTION | June 2022 | November 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17783703 | TREATMENTS OF DIABETIC MACULAR EDEMA AND IMPAIRED VISUAL ACUITY | June 2022 | November 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17833293 | FREEZE DRIED DRUG NANOSUSPENSIONS | June 2022 | July 2023 | Allow | 13 | 0 | 0 | No | No |
| 17779015 | PRODRUGS OF FULVESTRANT | May 2022 | January 2026 | Abandon | 44 | 0 | 1 | No | No |
| 17734331 | ANTAGONIST OF THE FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) FOR USE IN THE TREATMENT OR THE PREVENTION OF SKELETAL DISORDERS LINKED WITH ABNORMAL ACTIVATION OF FGFR3 | May 2022 | December 2023 | Abandon | 20 | 1 | 0 | No | No |
| 17726305 | METHOD OF PROVIDING BIRTH CONTROL | April 2022 | December 2023 | Abandon | 20 | 1 | 0 | No | No |
| 17720654 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | April 2022 | January 2026 | Allow | 45 | 1 | 1 | Yes | No |
| 17719220 | Phosphonate-Drug Conjugates | April 2022 | August 2025 | Allow | 40 | 2 | 1 | No | No |
| 17765202 | TREATMENT OF ALCOHOLIC HEPATITIS | March 2022 | November 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17705443 | USE OF CANNABIDIOL IN THE TREATMENT OF NOCTURNAL SNORING | March 2022 | December 2023 | Abandon | 21 | 1 | 0 | No | No |
| 17697729 | INOSITOL PHOSPHATE COMPOUNDS FOR USE IN TREATING, INHIBITING THE PROGRESSION, OR PREVENTING CARDIOVASCULAR CALCIFICATION | March 2022 | January 2025 | Abandon | 34 | 3 | 1 | No | No |
| 17642331 | TAK-925 FOR USE IN TREATING NARCOLEPSY | March 2022 | September 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17753706 | ALVELESTAT FOR USE IN THE TREATMENT OF GRAFT REJECTION, BRONCHIOLITIS OBLITERANS SYNDROME AND GRAFT VERSUS HOST DISEASE | March 2022 | February 2026 | Abandon | 47 | 1 | 1 | No | No |
| 17688081 | BENZOQUINONE DERIVATIVE E3330 IN COMBINATION WITH CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER AND ANGIOGENESIS | March 2022 | September 2024 | Abandon | 31 | 3 | 0 | No | No |
| 17651042 | DIHYDRATE OF BENZOTHIOPHENE COMPOUND OR OF A SALT THEREOF, AND PROCESS FOR PRODUCING THE SAME | February 2022 | November 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17670760 | ACEFAPC FOR THE TREATMENT OF ACETYLCHOLINE-DEPENDENT DISEASES | February 2022 | February 2024 | Abandon | 24 | 0 | 1 | No | No |
| 17592244 | METHODS OF TREATING EPILEPSY OR STATUS EPILEPTICUS | February 2022 | March 2024 | Allow | 25 | 1 | 0 | No | No |
| 17649780 | NASAL CANNABIDIOL COMPOSITIONS | February 2022 | May 2025 | Allow | 39 | 3 | 0 | Yes | No |
| 17582485 | DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF COUGH | January 2022 | July 2024 | Abandon | 30 | 2 | 1 | No | No |
| 17582513 | COMPOSITIONS COMPRISING CAROTENOIDS AND USE THEREOF | January 2022 | December 2023 | Abandon | 23 | 1 | 1 | No | No |
| 17627993 | Methods of treating sleep disorders associated with pain | January 2022 | September 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17573777 | New Potent Antimicrobial Compounds with a Pyridazine Nucleus | January 2022 | January 2023 | Allow | 12 | 2 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CORNET, JEAN P.
With a 24.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 13.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner CORNET, JEAN P works in Art Unit 1628 and has examined 1,290 patent applications in our dataset. With an allowance rate of 41.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 31 months.
Examiner CORNET, JEAN P's allowance rate of 41.3% places them in the 8% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by CORNET, JEAN P receive 2.23 office actions before reaching final disposition. This places the examiner in the 62% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by CORNET, JEAN P is 31 months. This places the examiner in the 54% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +53.5% benefit to allowance rate for applications examined by CORNET, JEAN P. This interview benefit is in the 95% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 17.0% of applications are subsequently allowed. This success rate is in the 15% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 17.7% of cases where such amendments are filed. This entry rate is in the 20% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 38.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 36% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 71.6% of appeals filed. This is in the 60% percentile among all examiners. Of these withdrawals, 66.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 66.8% are granted (fully or in part). This grant rate is in the 75% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 2.1% of allowed cases (in the 75% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.1% of allowed cases (in the 62% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.